Human lung tumor α1,3/4-L-fucosyltransferase (FT) was purified (2000-fold, 29% recovery) from 290 g of tissue by including a chromatography step on Affinity Gel-GDP. Two molecular forms (FTA, larger size carrying 15% α1,4-FT activity; FTB, the major form with 85% activity) were separated by further fractionation on a Sephacryl S-100 HR column. A difference in the electrophoretic mobilities of these two activities was also found on native polyacrylamide gel electrophoresis (PAGE). Both forms were devoid of typical α1,2-fucosylating activity but were associated with the novel α1 
Introduction
Numerous studies have demonstrated that many human tumors express fucosylated glycoconjugates that are absent in corresponding normal tissues, suggesting the presence of tumor associated α1,3-L-fucosyltransferases in human cancers (Alhadeff, 1989; Hakomori, 1989) . Immunohistochemical staining with a monoclonal antibody, FTA 1-16, against human α1,3/4 fucosyltransferase revealed an enhanced expression of this enzyme in cancer cells in comparison to normal cells (Kimura et al., 1995) . An inverse correlation was shown to exist between the survival of patients with primary lung cancer and the positive immunohistochemical staining of lung tumor by the monoclonal antibody M1A 15-5, which defines H/Le y /Le a antigens (Miyake et al., 1992 ). An indicator of poor prognosis in lung cancer was shown to be the expression of α1,3-L-fucosyltransferases Fuc T IV and Fuc T VII, which participate in the biosynthesis of sialyl Lewis x (Ogawa et al., 1996) . The frequency of sialyl Lewis a expression was identified as 69% in lung cancer (Ogawa et al., 1994) , whereas only 9% of lung tumors expressed Fuc T III. Such a discrepancy may be caused by the existence of a yet unknown α1,4-L-fucosyltransferase in human lung cancer (Ogawa et al., 1996) . It was reported that the α1,4-L-fucosyltransferase activity in human serum and saliva did not correlate with Lewis antigen status in erythrocytes (DeBose-Boyd et al., 1996) . The reason for this may be the fact that mutation in the catalytic domain of the Lewis gene would cause loss of enzyme activity, whereas that in the transmembrane domain may not affect the activity but affect the targeting of the enzyme to the Golgi apparatus (Nishihara et al., 1993; Machamer, 1993) .
The cellular expression of the Lewis blood group associated antigens Le a , Le b , and sialyl Le a is confined largely to endodermally derived tissues, such as lining epithelia and glandular epithelia (Szulman and Marcus, 1973; Oriol et al., 1986) . The coexistence of α1,3-and α1,4-fucosyltransferase activities in tissues expressing Lewis antigens make it difficult to assess the extent 1 To whom correspondence should be addressed to which the Lewis gene encoded enzyme contributes to the synthesis of Lewis x-related structures. The α1,3/4 fucosyltransferase of human A431 epidermoid carcinoma cell line exhibited only 11% activity toward Galβ1,4GlcNAc as compared to its activity on Galβ1,3GlcNAc (Johnson et al., 1993) . A recent investigation on human lung carcinoma cells NCI-H69 and PC9 indicated that the total fucosyltransferase activity in these cells was primarily comprised of Fuc-T IV and Fuc-T VI (Sherwood and Holmes, 1999) . The present article reports the partial purification, acceptor specificities, and kinetic properties of two molecular forms of α1,3/4-L-fucosyltransferase from human lung tumor (poorly differentiated mucinous adenocarcinoma of lung) displaying high substrate affinity for clustered units of 3-sialyl Galβ1,3GlcNAcβ-in asparagine linked carbohydrate as well as for mucin core 2 structure containing 3-sialyl Galβ1,4GlcNAcβ-unit, in addition to the novel α1,2-L-fucosylating activity.
Results

Purification of the α1,4-L-fucosyltransferase
The enzyme has been purified from 290 g of human lung tumor tissue, about 2000-fold as compared to the activity in Triton X-100 solubilized extract, by using (NH 4 ) 2 SO 4 fractionation followed by chromatography on an Affinity Gel-GDP (Table I) . When this purified enzyme preparation was subjected to SDSpolyacrylamide gel electrophoresis (PAGE), a single sharp band at ∼60 kDa was revealed on silver staining.
Isolation of two molecular forms of α1,4-L-fucosyltransferase from human lung tumor
When the Affinity Gel-GDP purified enzyme preparation was subjected to chromatography on a Sepharose S100 HR column, a larger molecular form containing ∼15% activity slightly less than 100,000 Da (it emerges quite adjacent to Vo), in addition to the major peak of activity at ∼65,000 Da (as evident from the MW marker) could be seen (Figure 1 ). The patterns of inhibition by N-ethyl maleimide on these two molecular forms of activity were observed to be the same, and K i was 0.25 mM in both cases (data not shown). Both enzyme forms, FTA (minor) and FTB (major), were examined for their acceptor specificities using a battery of synthetic compounds (see Table II ). Both forms lacked the typical α1,2-L-fucosyltransferase activity because Galβ-O-Bn did not act as their acceptor. Both FTA and FTB exhibited almost the same extent of activity (when expressed as a percent of the activity toward 2-O-MeGalβ1,3GlcNAcβ-O-Bn) toward the same acceptor. The only significant difference between the two forms was their activity toward 3′-sialyl LacNAc in mucin core 2, namely, NeuAcα2,3Galβ1,4GlcNAcβ1,6(Galβ1,3)GalNAcα-O-Me (activities: 24.2% versus 40.8%).
A comparison of the activities among the various acceptors revealed the following (see Table II ): The 3-O-unsubstituted LacNAc type 1 acceptor as compared to the corresponding LacNAc type 2 acceptors are 15-25 times more active with these enzymes. NeuAcα 2,3Galβ1,3 GlcNAcβ-O-Bn is ∼ ninefold as active as NeuAcα2,3Galβ1,4GlcNAcβ-O-Bn, whereas the latter as a part of mucin core 2 structure is nearly as active as the former (FTB: 64.4% and 40.8%, respectively). In fact, among the mucin core 2 acceptors tested, 3′-sialyl LacNAc in mucin core 2 structure was the best acceptor for these two molecular forms (see Table II ). Both forms showed considerable activity toward allyl glycosides containing substitution on C-4 OH or both C-4 and C-6 OH groups of the GlcNAc moiety, indicating the presence of novel α1,2-L-fucosylating activity. This is in accordance with our earlier report that this novel activity is associated with Lewis type α1,3/4-L-fucosyltransferase (Chandrasekaran et al., 1995b) . It is interesting to note that the Lewis a determinant attached to a Gal moiety, namely, Galβ1,3(Fucα1,4)GlcNAcβ1,3Galβ-O-Me, became a good acceptor for this novel α1,2-L-fucosylating activity in contrast to the nonreactivity of Galβ1,3(Fucα1,4)GlcNAcβ-O-Me (see Table II (Chandrasekaran et al., unpublished results); and (d) as to our knowledge the occurrence of internal α1,2-L-fucosyl Gal in carbohydrate chains has not been reported in the literature. Galβ1, 3(Fucα1, 4 
Characterization of the product arising from
)GlcNAcβ1,3Galβ-O-Me by the action of FTB
The [ 14 C] fucosyl compound isolated from the acceptor, Galβ1,3GlcNAcβ1,3Galβ-O-Me, by the action of FTB had the same mobility as the authentic synthetic compound, Figure 3A ) and the K m values were FTA, 2.5 mM and FTB, 1.0 mM ( Figure 3B ).
Activity of human lung tumor α1,4-L-fucosyltransferase toward glycoproteins and glycopeptides
FTB was used as the enzyme source for this study. The enzyme was found to be more active with sialylated glycoproteins than asialo glycoproteins (activities: fetuin 2.25, asialo fetuin 0.59; ancrod 40.33, and asialo ancrod 22.21; see Table III ). The best glycoprotein acceptor was ancrod, which contained several units of 3-sialylGalβ1,3GlcNAcβ-in the asparagine-linked carbohydrate chains. It is interesting to note that fetuin triantennary glycopeptide containing mainly 3-sialylGalβ1,4GlcNAcβ-units in asparagine linked chain was considerably less active than the corresponding asialo glycopeptide.
A comparison of the kinetics of FTA and FTB toward various synthetic acceptors
The major form (FTB) had maximum activity at 0.1 mM concentration of 3-O-SulfoGalβ1,3GlcNAcβ-O-Al, whereas the minor form (FTA) showed an increase in activity even beyond this concentration (K m FTA, 100 µM and FTB, 47 µM; Figure 4 ). On the other hand, the pattern of their activities toward 2-O-MeGalβ1,3GlcNAcβ-O-Bn appears to be the same (K m FTA, 400 µM and FTB, 160 µM; see Figure 4A ). The pattern of activities toward the sialylated acceptors, namely, NeuAcα2,3Galβ1,3GlcNAcβ-O-Bn and NeuAc-α2,3Galβ1,4GlcNAcβ1,6(Galβ1,3)GalNAcα-O-Me, were quite similar between FTA and FTB ( Figure 5A ). The K m values were FTA, 2.50 mM and FTB, 0.67 mM for the former acceptor and FTA, 3.33 mM and FTB, 0.77 mM for the latter (see Figure 5B ).
Further examination of the novel α1,2-L-fucosylating activity as well as the α1,3-L-fucosylating activity toward 2′-fucosyl lactose, using FTB Galβ1,3(4,6-di-O-Me)GlcNAcβ-O-Al served as the best acceptor for the novel α1,2-L-fucosylating activity followed by Galβ1,3(4-O-Me)GlcNAcβ-O-Al. Even the well-established activity of Lewis type, that is, the α1,3-L-fucosylating activity on 2′-fucosyl lactose was considerably lower than the transfer of Fuc to Galβ1, 3(4, 
Fucα1,2Galβ1,4Glc gave, respectively, the following K m values: 0.60 mM, 2.63 mM, 6.00 mM, 10.00 mM, 7.10 mM, and 1.52 mM (see Figure 6B ).
Association of novel α1,2-L-fucosylating activity with human lung adenocarcinoma α1,4-L-fucosyltransferase FTB was used as the enzyme source. When α1,4-L-fucosyltransferase activity was measured with increasing concentration of the acceptor, 3-O-sulfoGalβ1,3GlcNAcβ-O-Al, in the presence of Galβ1,3(4,6 di-O-Me)GlcNAcβ-O-Al (3.0 mM), which is an acceptor for the novel α1,2-fucosylating activity, an inhibition of the former activity as well as mutual inhibition of the latter activity were observed ( Figure 7A ). Conversely, when the novel α1,2-L-fucosylating activity was measured with increasing concentration of the acceptor, Galβ1,3(4,6 di-O-Me)GlcNAcβ-OAl, in the presence of 3-O-sulfoGalβ1,3GlcNAcβ-O-Al (3.0 mM), mutual inhibition of both activities occurred ( Figure 7B ).
Macromolecular substrate activity analysis of human lung tumor α1,4-L-fucosyltransferase
Ancrod showed saturating activity at 80 µg (0.114 mM), whereas asialo ancrod required >100 µg (0.133 mM) to reach maximum activity. Fetuin triantennary asialo glycopeptide showed maximum activity at 80 µg (1.0 mM), and the corresponding sialoglycopeptide needed 200 µg for maximum activity. The K m values ( Figure 8B ) were as follows: ancrod 45 µM; asialo ancrod 167 µM; fetuin triantennary glycopeptide 1.43 mM; and the corresponding asialo glycopeptide 0.63 mM.
Further evidence for the existence of two molecular forms of α1,4-L-fucosyltransferase in human lung tumor
When FTA and FTB were subjected to native PAGE, we were able to locate the enzyme activity on the gel after slicing and eluting the gel slices. During this operation, the loss of enzyme activity was low with FTB as compared to FTA. From Figure 9 it is evident that the mobility of FTA activity on the gel was higher than that of FTB, suggesting an association of higher anionic charge with FTA.
Discussion
A considerable degree of α1,3/4-L-fucosyltransferase purification from a limited source, such as human lung tumor, has been achieved. The occurrence of two molecular forms of this enzyme has been demonstrated by molecular sieve chromatography on Sephacryl S-100 HR column and also by showing the difference in their mobilities by following their activity profiles after native PAGE. Further we have given an indication that native PAGE under the experimental conditions used could be a method for further purification of a small amount of α1,3/4-L-fucosyltransferase, or probably any other glycosyltransferase obtained, after a considerable extent of purification from a limited source.
The striking features of the two molecular forms of this enzyme from human lung tumor are as follows: The ratio of their activities with simple type I and type 2 LacNAc acceptor substrates closely resembles those of α1,3/4-fucosyltransferases purified from human milk (Johnson et al., 1992) and the culture media of human A431 epidermoid carcinoma cell line (Johnson et al., 1993) , the activity being more than 10-fold greater toward type 1 acceptor. But there are subtle differences between these enzymes and the lung tumor FTA and FTB. Human milk and A431 cell line α1,3/4-FTs showed considerably reduced activity (46%) when sialic acid is linked to α2,3 to the terminal β-galactosyl residue of type 1 structure, Table III . Human lung tumor molecular form B α-1,4-L-fucosyltransferase activity toward glycoproteins and glycopeptides This enzyme does not have the typical α1,2-L-fucosylating activity (that is, adding Fuc to any terminal Gal), but has the novel α1,2-L-Fucosylating activity (that is, adding Fuc to the terminal Gal moiety in Lewis a structure, Galβ1,3[Fucα1,4]GlcNAcβ-). Thus, it is apparent that this enzyme adds Fuc to the above glycoprotein and glycopeptide acceptors, predominantly in α1,4-and a few in α1,3-L-linkages. whereas FTA and FTA exhibited almost the same extent of activity with α2,3-sialylated Type 1 acceptors. 3′-Sialyl LacNAc type 2 was one third as active as 3′-sialyl LacNAc type 1 in case of α1,3/4FTs of human milk and A431 cell line, whereas this activity was only about one tenth with FTA and FTB, which is quite similar to the behavior of FTA and FTB toward asialo acceptors. In contrast to > twofold activity exhibited by A431 cell line α1,3/4-FT toward 2′-fucosyllactose, both FTA and FTB were only ∼60% active toward this acceptor as compared to 3′-sialyl LacNAc type 1 acceptor.
Furthermore, we made a remarkable observation that 3′-sialyl LacNAc type 2 in mucin core 2 structure, namely, NeuAcα2,3Galβ1,4GlcNAcβ1,6(Galβ1,3)GalNAcα-O-Me, is four to five times active as NeuAcα2,3Galβ1,4GlcNAcβ-O-Bn, and the acceptor efficiency is 43% and 63% that of NeuAcα2,3Galβ1,3GlcNAcβ-O-Bn toward FTA and FTB, respectively. In fact, even other substitutions (such as methyl or sulfate group) on C-3 OH of β1,4-linked Gal of mucin core 2 increased the efficiency of these acceptors about five to eightfold (see Table II ).
In an earlier study (Chandrasekaran et al., 1995b) we have shown an association of a novel α1,2-L-fucosylating activity, which leads to the expression of blood group Lewis b determinant from Lewis a,with the Lewis type α1,3/4-L-fucosyltransferase. In the present study we have shown that FTA and FTB can fucosylate the acceptors Galβ1,3(Fucα1,4)GlcNAcβ-O-Al, Galβ1,3(4-O-Me)GlcNAcβ-O-Al, Galβ1,3(4,6-di-O-Me)GlcNAcβ-O-Al, and Galβ1,3(Fucα1,4)GlcNAcβ1,3Galβ-O-Me. The efficiencies of accepting Fuc by Galβ1,3(Fuc− α1,4)GlcNAcβGal-O-Me and Galβ1,3(4,6-di-O-Me)GlcNAcβ-O-Al are remarkably equal or greater than that of Galβ1,3GlcNAc. Johnson et al. (1993) found Galβ1,3(Fucα1,4)GlcNAcβ1,3Galβ1,4Glc as equally good as Galβ1,3GlcNAc as an acceptor for A431 carcinoma cell line α1,3/4-FT. Unfortunately, they did not attempt to locate the transferred radioactive Fuc in the product, but might have assumed its location as the Glc moiety in parallel to the product from 2′-fucosyl lactose.
A determination of K m values for a number of synthetic acceptors indicated that the most efficient one was the LacNAc type 1 acceptor containing a sulfate substituent on C-3 of Gal followed by the acceptors containing methyl or sialyl groups as C-3 substituents (K m : 0.10 mM, 0.40 mM, and 2.50 mM for FTA and 0.047 mM, 0.16 mM, and 0.67 mM for FTB, respectively). The K m determined for another efficient acceptor 3′-sialyl LacNAc type 2 in mucin core 2 structure, namely, NeuAcα2,3Galβ1,4GlcNAcβ1,6(Galβ1,3)GlcNAcα-O-Me, was 3.33 mM for FTA and 0.77 mM for FTB. In general FTA was lethargic in its activity as compared to FTB, probably due to its larger size. Johnson et al. (1993) used carbohydrate acceptors containing no aglycans in their study on cell line A431 α1,3/4-FT, and the K m values they reported were generally much higher than the values we obtained in the present study for FTA and FTB. This could be explained by their data that the one acceptor with an aglycan Galβ1,3GlcNAc-O-(CH 3 ) 8 COOMe they examined was superior to Galβ-1,3GlcNAc (K m 0.3 mM and 3.0 mM, respectively).
Among the high molecular weight acceptors, ancrod serves as the best acceptor for α1,3/4-FT of human lung tumor. Ancrod, a thrombin-like serine protease isolated from the venom of the Malayan pit viper Agkistrodon rhodostoma (Nolan et al., 1976) , is a glycoprotein (36% carbohydrate by weight) of 35 kDa containing complex type N-glycans (di-, tri-, and tetraantennary carrying NeuAcα2,3Galβ1,3GlcNAcβ-in a molar ratio [mol/100 mol] 23:40:12) (Pfeiffer et al., 1992) . Thus, clusters of oligosaccharides containing NeuAc-α2,3Galβ1,3GlcNAcβ-seem to be the best target of this enzyme for action. After the removal of sialic acid, the activity of the enzyme on the asialo acceptor, that is, asialo ancrod, dropped to ∼50%. On the other hand, fetuin triantennary glycopeptide, which has been shown to contain NeuAc-α2,3Galβ1,4GlcNAcβ-in two antennae and a combination of NeuAcα2,3Galβ1,4GlcNAcβ-and NeuAcα2,3Galβ1,3GlcNAcβ-on the third (Townsend et al., 1986) , was less efficient than the corresponding asialo acceptor. This would suggest that NeuAcα2,3Galβ1,4GlcNAcβ-cluster in a triantennary chain has a negative influence on this enzyme activity. The enzyme appears to like sialylated glycoproteins; this becomes evident from the finding that fetuin, bovine α 1 -acid glycoprotein, and carcinoembryonic antigen served as better acceptors than asialo fetuin.
When the acceptor substrate specificity of the Lewis enzymes was characterized by site-directed mutagenesis (Depuy et al., 1999) it was found that Trp 111 of hypervariable stem domain is responsible for the specificity of fucose transfer to H-type 1 acceptors, and the acidic residue Asp 112 is essential for this enzyme activity. It was also found that more than Trp and Asp are probably necessary to change the specificity of bovine fut b-encoded α1,3-L-fucosyltransferase from type 2 activity to type 1 (Depuy et al., 1999) . Consistent with this observation, a very small increase in the number of cells producing Le a and sialyl Le a antigens was observed in cells transfected by a Fuc-T VI chimera containing Fuc-T III subdomains 4 and 5 (positions 103-153) (Legault et al., 1995) . It was also shown that two amino acid changes in Fuc-T V (Asp 86 → His and Thr 87 → Ile) increased the type 1 activity of the recombinant enzyme (Nguyen et al., 1998) . The molecular phylogeny of fucosyltransferase genes suggests that the common ancester of FUT 3 and FUT 5 genes has acquired the capacity to use type 1 acceptors without loss of the activity to use type 2 acceptors (Oulmouden et al., 1997) . It is interesting to note that the α1,3/4-fucosyltransferase of human lung tumor seems to have a very low capacity to fucosylate type 2 acceptors, indicating that other independent mutations might have contributed to this change. Lo-Guidice et al. (1995) identified a sulfotransferase in human respiratory mucosa responsible for the 3-O-sulfation of terminal Gal in LacNAc, containing mucin carbohydrate chains. Subsequently the same group (Lo-Guidice et al., 1997) reported the occurrence of the carbohydrate chain 3-OSulfoGalβ1,3(Fucα1,4)GlcNAcβ1,3Galβ1,3GalNAcα-in respiratory mucins of a nonsecretor (O, Le a+b-) patient suffering from chronic bronchitis. Consistent with their findings, the present study has found that 3-O-SulfoGalβ1,3GlcNAcβ-is a high affinity acceptor substrate for human lung tumor (mucinous adenocarcinoma) α1,3/4-L-fucosyltransferase. 
Materials and methods
Purification of α1,4-L-fucosyltransferase from human lung tumor (non-small cell poorly differentiated mucinous adenocarcinoma in upper lobe of right lung)
The tumor was obtained during autopsy of a 58-year-old Caucasian female patient at Roswell Park Cancer Institute and stored at -70°C until processing. The tumor (291.5 g) was cut into small pieces in the cold room and homogenized with 1460 ml of ice-cold buffer (0.1 M Tris maleate, pH 6.3, containing 2% Triton X-100, 5 mM Mn acetate, 35 µm PMSF, and 0.1% NaN 3 ) using Kinematica on an ice bath. The homogenate was centrifuged at 10,000 × g for 1 h at 5°C. The fat-free supernatant was adjusted to 20% saturation of (NH 4 ) 2 SO 4 , stirred in the cold room for 0.5 h, and centrifuged as above. The supernatant was adjusted to 20-60% saturation of (NH 4 ) 2 SO 4 and centrifuged as above. The precipitate was dissolved in 450 ml of the above buffer and dialyzed against the same buffer for 24 h in the cold room with four changes. The dialyzed 20-60% (NH 4 ) 2 SO 4 fraction (510 ml) was subjected to affinity chromatography on an Affinity Gel-GDP (Calbiochem; 10 µm GDP/ml gel slurry) column (2.5 × 4.0 cm) (20 ml bed volume) in batches of 100 ml. The column had been equilibrated with the same buffer. After the entry of the sample (100 ml), the column was washed with 100 ml of the same buffer. The affinity column was then eluted with 60 ml of the same buffer containing 0.5 mM GDP. Then the column was washed with 100 ml of the same buffer containing 2 M NaCl and then equilibrated with the buffer for the fractionation of the second batch of 100 ml as above. The GDP eluates from the five batches of operation were pooled, concentrated by Amicon ultra filtration using PM 10 membrane, then dialyzed exhaustively against 50 mM Tris maleate, pH 6.3, containing 2% Triton X-100 and 0.1% NaN 3 . The α1,4-fucosyltransferase activity of this preparation (4 ml) was stable for at least 6 months when stored at -20°C. 
Glycoproteins and glycopeptides
Fetuin, asialo fetuin, bovine α 1 acid glycoprotein, bovine IgG, and apotransferrin were purchased from Sigma. Fetuin triantennary glycopeptide, fetuin triantennary asialoglycopeptide, bovine IgG diantennary glycopeptide, and carcinoembryonic antigen were available from our earlier studies (Chandrasekaran et al., 1983 (Chandrasekaran et al., , 1995b . Asialo apotransferrin was made by heating apotransferrin at 80°C in 0.1 N HCl for 1 h, neutralizing with 0.1 N NaOH, dialyzing against water in the cold room for 24 h, and then lyophilizing. Highly purified ancrod (a thrombin-like serine protease) (Nolan et al., 1976; Pfeiffer et al., 1992) was a generous gift from Dr. Chris Nolan of Abbott Labs (Chicago, IL). Asialo ancrod was prepared from ancrod as described above.
Synthetic compounds
We have already reported the synthesis of several compounds used in the present study (Jain et al., 1993 (Jain et al., , 1994 (Jain et al., , 1998 Chandrasekaran et al., 1995a Chandrasekaran et al., , 1997 . The chemical synthesis of NeuAcα2,3Galβ1,4GlcNAcβ1,6(Galβ1,3) GalNAcα-O-Me will be reported elsewhere.
Assay of α1,4-fucosyltransferase
The incubation mixtures run in duplicate contained 50 mM HEPES-NaOH, pH 7.5, 5 mM MnCl 2 , 7 mM ATP, 3 mM NaN 3 , the acceptor (3.0 mM unless otherwise stated), 0.05 µCi of GDP-[U-14 C]Fuc (specific activity 290 mCi/mmol), and this enzyme in a total volume of 20 µl; the control incubation mixtures had everything except the acceptor. At the end of incubation for 2 h at 37°C, the mixture was diluted with 1.0 ml of water and passed through a Dowex-1-Cl column (1 ml in a Pasteur pipet) (Chandrasekaran et al., 1992) . The column was washed twice with 1 ml water; the breakthrough and wash that contained the [ 14 C] fucosylated neutral acceptor were collected together in a scintillation vial, and the radioactive content was determined using 3a70 scintillation fluid (Research Products International, Mount Prospect, IL) and a Beckman LS9000 instrument. The Dowex column was then eluted with 3.0 ml of 0.2 M NaCl to obtain the [ 14 C] fucosylated product from sialylated/sulfated acceptors and then counted for radioactivity as before. Corrections were made by subtracting the radioactivity in the water and NaCl eluates of the control incubation mixtures from the values of the corresponding eluates of the tests. Duplicate sample values did not vary more than 5%.
Gel chromatography
Two milliliters of the Affinity Gel-GDP purified α1,3/4-fucosyltransferase preparation from human lung tumor was applied to a Sephacryl S-100 HR column (2.5 × 118.0 cm) at 4°C equilibrated and eluted with 0.1 M Tris maleate, pH 6.3, containing 0.1% Triton X-100 and 0.02% NaN 3 . Fractions of 2 ml at a flow rate of 6 ml per h were collected, and 10 µl of alternate fraction were assayed for α1,4-fucosyltransferase activity using 2-O-MeGalβ1,3GlcNAcβ-O-Bn as the acceptor.
PAGE
Ready-made polyacrylamide gels (10% resolving gel and 4% stacking gel containing no SDS) were used for both native as well as SDS-PAGE. Bio-Rad Mini-Protean II Electrophoresis Cell was used. Native PAGE was performed in the cold room with Tris-glycine pH 8.3 containing 0.1% Triton X-100. The enzyme sample 100 µl was mixed with 100 µl of 2× buffer containing glycerol, Triton X-100, and bromophenol blue applied in equal volume (33 µl) to each of the middle six wells and run at 30 mA/gel using Bio-Rad Power Pac 1000 at 200 constant volts. After electrophoresis each gel was removed and cut into 3-mm slices (22 slices total). Each gel slice was shaken in the cold room in 200 µl of 0.1 M HEPES-NaOH, pH 7.0, containing 2% Triton X-100 and 0.1% NaN 3 for 24 h using speci mix (Thermolyne). The gel eluates were assayed for α1,4-fucosyltransferase activity by using the acceptor 2-OMeGalβ1,3GlcNAcβ-O-Bn. SDS-PAGE was performed at room temperature in Tris glycine, pH 8.3, containing 0.1% SDS. The sample was mixed with equal volume of 2× sample loading buffer containing SDS, mercaptomethanol, glycerol, and bromophenol blue and denatured in boiling water bath for 5 min before the electrophoretic run. The gels were stained using a Bio-Rad silver staining kit. Galβ1, 3GlcNAcβ1, 3(Fucα1, 4 
Identification of the products arising from
)GlcNAcβ1,3Galβ-O-Me by the action of FTB
A 10-fold reaction mixture (200 µl) containing Galβ1,3GlcNAcβ1,3Galβ-O-Me and another containing Galβ1,3(Fucα1,4)GlcNAcβ1,3Galβ-O-Me were incubated for 4 h at 37°C. After incubation the reaction mixtures were diluted with 1 ml water then subjected to chromatography on a Biogel P-2 column (1.0 × 116 cm) utilizing 0.1 M pyridine acetate, pH 5.4, as the eluting buffer. Fractions appearing under the first peak containing the [ 14 C] fucosyl compound were pooled in each case, lyophilized to dryness, and dissolved in 200 µl water. These radioactive samples were subjected to thin-layer chromatography on silica gel GHLF (Analtech, 250 microns, scored 20 cm × 20 cm) plates developed in two different solvent systems; 1-butanol/acetic acid/water (3:2:1) and 1-propanol/NH 4 OH [25%]/water (12:2:5), along with Galβ1,3GlcNAcβ1,3Galβ-O-Me and Galβ1,3(Fucα1,4)GlcNAcβ1,3Galβ-O-Me markers. The radioactive content of 0.5 cm width segments scraped into scintillation vials and soaked in 2 ml water was determined by liqiud scintillation spectroscopy. Autoradiography was carried out at -70°C using Biomax MR film (Kodak) after spraying plates with EnHance (DuPont).
